2-甲基-2-丙基2-(2-丙炔-1-基)肼羧酸酯 | 406683-19-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-甲基-2-丙基2-(2-丙炔-1-基)肼羧酸酯
• 英文名称: N-propargyl tert-butyl carbazate
• 英文别名: tert-Butyl 2-(prop-2-yn-1-yl)hydrazine-1-carboxylate；tert-butyl N-(prop-2-ynylamino)carbamate
• CAS: 406683-19-0
• 化学式: C₈H₁₄N₂O₂
• 分子量: 170.211
• InChiKey: VCOQYSBEWCMFFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-甲基-2-丙基2-(2-丙炔-1-基)肼羧酸酯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 2,6-二叔丁基-4-甲基苯酚 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 N-[(tert-butoxy)carbonylamino][7-chloro-4-oxo-2-(pyrrolidinylcarbonyl)(3-hydroxyquinolyl)]-N-(3-(4-pyridyl)prop-2-ynyl)carboxamide
  参考文献：
  名称：

  Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain

  摘要：

  A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.

  DOI：

  10.1021/jm060212s
• 作为产物：
  描述：

  肼基甲酸叔丁酯 、 3-溴丙炔 在 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 以54%的产率得到2-甲基-2-丙基2-(2-丙炔-1-基)肼羧酸酯
  参考文献：
  名称：

  [EN] NOVEL CYCLIC PEPTIDES AND USES THEREOF
  [FR] NOUVEAUX PEPTIDES CYCLIQUES ET LEURS UTILISATIONS

  摘要：

  本发明涉及公式（I）的新型环状肽GHRP-6类似物，以及其药学上可接受的酯或盐。这些环状肽GHRP-6类似物可用于调节CD36活性，例如用于治疗CD36相关疾病、失调或状况，如动脉粥样硬化和年龄相关性黄斑变性。

  公开号：

  WO2018000079A1

文献信息

• Highly selective arylation of disubstituted hydrazines by pentavalent organobismuth reagents
  作者：Olga Tšubrik、Uno Mäeorg、Ulf Ragnarsson

  DOI：10.1016/s0040-4039(02)01327-8

  日期：2002.8

  The scope of a set of recently reported hydrazine reagents has been explored with respect to arylation. Compounds of type R1NHNHCOR2 can be selectively arylated under very mild conditions using triarylbismuth diacetates.

  关于芳基化，已经研究了一组最近报道的肼试剂的范围。可以使用二乙酸三芳基铋在非常温和的条件下将R 1 NHNHCOR 2类型的化合物选择性芳基化。
• Combinatorial Aid for Underprivileged Scaffolds: Solution and Solid-phase Strategies for a Rapid and Efficient Access To Novel Aza-diketopiperazines (Aza-DKP)
  作者：Dominique Bonnet、Jean-François Margathe、Sally Radford、Elsa Pflimlin、Stéphanie Riché、Pete Doman、Marcel Hibert、A. Ganesan

  DOI：10.1021/co300015k

  日期：2012.5.14

  An efficient solution-phase synthesis of aza-diketopiperazines (aza-DKP, triazinediones) is reported. A structurally diverse collection of c-[aza-alkylGly-Pro] derivatives and yet unreported 2,4,5-trisubstituted-1,2,4-triazine-3,6-diones has been synthesized starting from Fmoc-L-Pro-OH and various Fmoc-L-amino acids. To extend the practical value of this class of dipeptidomimetics, a general solid-phase synthesis approach amenable to library production was developed on both Wang-PS and HMBA-PS resins. The final acidic treatment of the resins in TFA/water mixture at room temperature enabled the rapid and quantitative cyclization/release highly pure triazinediones. The conformational preferences and the spatial organization of the three substituents of a representative 2,4,5-trisubstituted-1,2,4-triazine-3,6-dione were investigated by X-ray diffraction and H-1 NMR spectroscopy.
• Diversity-Oriented A³-Macrocyclization for Studying Influences of Ring-Size and Shape of Cyclic Peptides: CD36 Receptor Modulators
  作者：Ragnhild G. Ohm、Mukandila Mulumba、Ramesh M. Chingle、Ahsanullah、Jinqiang Zhang、Sylvain Chemtob、Huy Ong、William D. Lubell

  DOI：10.1021/acs.jmedchem.1c00642

  日期：2021.7.8
• NOVEL CYCLIC PEPTIDES AND USES THEREOF
  申请人：VALORISATION-RECHERCHE, LIMITED PARTNERSHIP

  公开号：US20190202863A1

  公开（公告）日：2019-07-04

  Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of CD36-related diseases, disorders or conditions in a subject, such as atherosclerosis and age-related macular degeneration.
• US9845493B2
  申请人：——

  公开号：US9845493B2

  公开（公告）日：2017-12-19